ILT3 blockade shows no monotherapy activity while a combo runs into toxicity issues, but Merck presses on.
The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
With four pivotal tiragolumab readouts, Roche’s 2022 will not only be the year of Alzheimer’s.
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.
Here's a roundup of Vantage's coverage of the 2021 European Society for Medical Oncology congress.